Comment

. 2024 Jun;177(6):JC67.

doi: 10.7326/ANNALS-24-00447-JC. Epub 2024 Jun 4.

In complicated UTIs, cefepime-taniborbactam increased treatment success vs. meropenem at 19 to 23 d

Bruno Granwehr¹

Affiliations

PMID: 38830218
DOI: 10.7326/ANNALS-24-00447-JC

Comment

In complicated UTIs, cefepime-taniborbactam increased treatment success vs. meropenem at 19 to 23 d

Bruno Granwehr. Ann Intern Med. 2024 Jun.

. 2024 Jun;177(6):JC67.

doi: 10.7326/ANNALS-24-00447-JC. Epub 2024 Jun 4.

Author

Bruno Granwehr¹

Affiliation

¹ University of Texas MD Anderson Cancer Center, Houston, Texas, USA (B.G.).

PMID: 38830218
DOI: 10.7326/ANNALS-24-00447-JC

Abstract

Wagenlehner FM, Gasink LB, McGovern PC, et al; CERTAIN-1 Study Team. Cefepime-taniborbactam in complicated urinary tract infection. N Engl J Med. 2024;390:611-622. 38354140.

PubMed Disclaimer

Conflict of interest statement

Disclosures: Disclosure forms are available with the article online.

Comment on

Cefepime-Taniborbactam in Complicated Urinary Tract Infection.
Wagenlehner FM, Gasink LB, McGovern PC, Moeck G, McLeroth P, Dorr M, Dane A, Henkel T; CERTAIN-1 Study Team. Wagenlehner FM, et al. N Engl J Med. 2024 Feb 15;390(7):611-622. doi: 10.1056/NEJMoa2304748. N Engl J Med. 2024. PMID: 38354140 Clinical Trial.

Similar articles

Patient outcomes by baseline pathogen resistance phenotype and genotype in CERTAIN-1, a Phase 3 study of cefepime-taniborbactam versus meropenem in adults with complicated urinary tract infection.
Moeck G, Gasink LB, Mendes RE, Woosley LN, Dorr M, Chen H, Wagenlehner FM, Henkel T, McGovern PC. Moeck G, et al. Antimicrob Agents Chemother. 2024 Jul 9;68(7):e0023624. doi: 10.1128/aac.00236-24. Epub 2024 May 23. Antimicrob Agents Chemother. 2024. PMID: 38780262 Free PMC article. Clinical Trial.
Cefepime-taniborbactam and CERTAIN-1: Can we treat carbapenem-resistant infections?
Bassetti M, Giacobbe DR. Bassetti M, et al. Med. 2024 May 10;5(5):380-382. doi: 10.1016/j.medj.2024.03.011. Med. 2024. PMID: 38733970
Cefepime-Taniborbactam in Complicated Urinary Tract Infection.
Manesh A, Varghese GM, Paterson DL. Manesh A, et al. N Engl J Med. 2024 May 30;390(20):1938. doi: 10.1056/NEJMc2403590. N Engl J Med. 2024. PMID: 38810201 No abstract available.
Cefepime-Taniborbactam: A Novel Cephalosporin/β-Lactamase Inhibitor Combination.
Zhanel GG, Mansour C, Mikolayanko S, Lawrence CK, Zelenitsky S, Ramirez D, Schweizer F, Bay D, Adam H, Lagacé-Wiens P, Walkty A, Irfan N, Clark N, Nicolau D, Tascini C, Karlowsky JA. Zhanel GG, et al. Drugs. 2024 Oct;84(10):1219-1250. doi: 10.1007/s40265-024-02082-9. Epub 2024 Aug 30. Drugs. 2024. PMID: 39214942 Review.
Treatment of urinary tract infections in the era of antimicrobial resistance and new antimicrobial agents.
Bader MS, Loeb M, Leto D, Brooks AA. Bader MS, et al. Postgrad Med. 2020 Apr;132(3):234-250. doi: 10.1080/00325481.2019.1680052. Epub 2019 Oct 24. Postgrad Med. 2020. PMID: 31608743 Review.

See all similar articles

References

Publication types

Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions
Actions
Actions

LinkOut - more resources

Full Text Sources
- Atypon
- Ovid Technologies, Inc.
Medical
- MedlinePlus Health Information

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

In complicated UTIs, cefepime-taniborbactam increased treatment success vs. meropenem at 19 to 23 d

Affiliation

In complicated UTIs, cefepime-taniborbactam increased treatment success vs. meropenem at 19 to 23 d

Author

Affiliation

Abstract

Conflict of interest statement

Comment on

Similar articles

References

Publication types

MeSH terms

Substances

LinkOut - more resources

Full Text Sources

Medical

Abstract

Conflict of interest statement

Comment on

Similar articles

References

Publication types

MeSH terms

Substances

Related information

LinkOut - more resources

Full Text Sources

Medical